Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
Study title | Condition | Phase | Location |
---|---|---|---|
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation |
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms | Phase 1, Phase 2 | United States Netherlands Spain China Italy Japan Denmark Germany Hong Kong Belgium France Australia Canada Korea, Republic of Singapore Taiwan View All |
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria |
Severe Malaria | Phase 2 | Côte D'Ivoire Burkina Faso Nigeria Rwanda Congo, The Democratic Republic of the Gabon India Kenya View All |
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection |
Melanoma | China | |
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study |
Sickle Cell Disease | Phase 4 | Turkey United States Lebanon Belgium Colombia France Germany Spain Oman Italy Brazil View All |
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations |
NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations | Phase 2 | Italy Czech Republic United States United Kingdom Spain Turkey France Japan Canada View All |
Secukinumab Open Label Roll-over Extension Protocol |
Autoimmunity, Inflammation | Phase 4 | United States China Poland Colombia Czech Republic Mexico Guatemala Brazil South Africa Bulgaria Spain View All |
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. |
Acute Myeloid Leukemia | Phase 1, Phase 2 | Spain |
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum |
PIK3CA-related Overgrowth Spectrum (PROS) | Phase 2 | United States Switzerland France Germany Spain United Kingdom Canada Netherlands Hong Kong Italy China View All |
Special Drug Use-results Surveillance of Tabrecta Tablets |
Non-small Cell Lung Cancer | Japan | |
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy |
Primary IgA Nephropathy | Phase 3 | United States Denmark Australia Israel India Thailand China Norway Germany Korea, Republic of Argentina Brazil Belgium Netherlands Hong Kong Turkey Taiwan Malaysia Japan United Kingdom Italy Canada France Czech Republic Singapore View All |
Pagination
- ‹‹ Previous page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- ›› Next page